GIS:FRA
Gilead Sciences, Inc
€139.42
arrow_upward
+0.36%(+0.50) 1D
Oct 19, 8:00:18 AM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GIS...
Open
€139.42
High
€139.42
Low
€139.42
Mkt. cap
191.55B
Avg. vol.
397.00
Volume
0.00
52-wk high
€142.00
52-wk low
€97.79
No. of employees
17K
Open
€139.42
High
€139.42
Low
€139.42
Mkt. cap
191.55B
Avg. vol.
397.00
Volume
0.00
52-wk high
€142.00
52-wk low
€97.79
No. of employees
17K
News stories
From web sources and news partners
ad-hoc-news.de
·
1 hour ago
Gilead Sciences stock: BofA lifts target for Gilead Sciences stock to USD 164.00
STAT
·
2 hours ago
Pharmalittle: We're reading about Roche investments in Germany, a Gilead bowel disease drug, and more
Investing.com
·
3 hours ago
Gilead to present HIV and antiviral research at IDWeek 2026
Yahoo Finance
·
4 hours ago
43 ETFs Add to Gilead Sciences (GILD) on Thursday
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences, Inc
CEODaniel O'Day
Employees17K
FoundedJun 22, 1987
HeadquartersFoster City, California, United States
SectorBiotechnology
Websitegilead.com